Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, ODI Pharma AB's enterprise value is kr36.94 Mil.
ODI Pharma AB's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was kr2.15 Mil. Therefore, ODI Pharma AB's EV-to-EBITDA for today is 17.21.
The historical rank and industry rank for ODI Pharma AB's EV-to-EBITDA or its related term are showing as below:
XSAT:ODI'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -833.24 Med: -10.96 Max: 184.85
Current: 17.22
During the past 8 years, the highest EV-to-EBITDA of ODI Pharma AB was 184.85. The lowest was -833.24. And the median was -10.96.
XSAT:ODI's EV-to-EBITDA is ranked worse than 61.85% of 726
companies
in the Drug Manufacturers industry
Industry Median: 13.75
vs XSAT:ODI: 17.22
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
ODI Pharma AB's PE Ratio (TTM) for today is calculated as:
ODI Pharma AB's share price for today is kr2.20.
ODI Pharma AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.090.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for ODI Pharma AB's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, ODI Pharma AB's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ODI Pharma AB EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, ODI Pharma AB's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where ODI Pharma AB's EV-to-EBITDA falls into.
ODI Pharma AB's current Enterprise Value is kr36.94 Mil.
ODI Pharma AB's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr2.15 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ODI Pharma AB (XSAT:ODI) has a EV-to-EBITDA of 17.21 as of Sep. 08, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on ODI Pharma AB. According to the industry distribution chart, ODI Pharma AB ranks #449 out of 726 companies in the Drug Manufacturers industry, placing it in the top 61.8%.
Is ODI Pharma AB's EV-to-EBITDA too high?
ODI Pharma AB's current EV-to-EBITDA is 17.21. The Drug Manufacturers industry median EV-to-EBITDA is 13.75. ODI Pharma AB's value of 17.21 is 25.2% above this industry median. Based on the distribution chart, ODI Pharma AB ranks #449 out of 726 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, ODI Pharma AB has a GF Score™ of 48/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does ODI Pharma AB's EV-to-EBITDA compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, ODI Pharma AB ranks #449 out of 726 companies for EV-to-EBITDA. This places ODI Pharma AB in the lower half of its industry. The industry median EV-to-EBITDA is 13.75. ODI Pharma AB's value of 17.21 is 25.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.75, based on 726 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ODI Pharma AB's current EV-to-EBITDA of 17.21 is 25.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on ODI Pharma AB. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ODI Pharma AB's current EV-to-EBITDA is 17.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ODI Pharma AB stock overvalued right now?
Based on GuruFocus' analysis, ODI Pharma AB (XSAT:ODI) is currently considered Possible Value Trap. The stock's GF Value™ is kr7.07, compared to a current price of kr2.20 — trading 68.9% below its estimated fair value. The current EV-to-EBITDA is 17.21 and 25.2% above the Drug Manufacturers industry median of 13.75. ODI Pharma AB's overall GF Score™ is 48/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For ODI Pharma AB (XSAT:ODI), the current EV-to-EBITDA is 17.21 as of Sep. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ODI Pharma AB (XSAT:ODI) Overvalued in 2026?
Based on GuruFocus' analysis, ODI Pharma AB stock appears to be undervalued.
The current stock price of kr2.20 is trading 68.9% below its estimated GF Value™ of kr7.07.
GuruFocus considers ODI Pharma AB to be Possible Value Trap.
Key valuation signals for XSAT:ODI:
EV-to-EBITDA: 17.21
GF Value™: kr7.07 vs. price of kr2.20 (68.9% below fair value)
Industry Position: 25.2% above the Drug Manufacturers median (#449 of 726)
No single metric tells the full story. See the XSAT:ODI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSAT:ODI has been successfully added to your 
